Why did Sun Pharma acquire Ranbaxy?

Key Impact and Rationale of the transaction: The transaction will combine Sun Pharma’s proven complex product capabilities with Ranbaxy’s strong global footprint, leading to significant value creation opportunities.

Is Ranbaxy and Sun Pharma same?

Sun Pharma completed the acquisition of Ranbaxy Laboratories Limited, an integrated, research based, international pharmaceutical company, on 25th March 2015.

Why was Ranbaxy sold?

After the death of their father Parvinder Singh in 1999, they inherited 33.5\% stake in Ranbaxy. They sold Ranbaxy at its peak and got much media attention for the money it fetched. the sale proceeds was fuelled their ambitions and they invested the money for expansion of Fortis Healthcare and Religare.

What does Sun Pharma make?

Sun Pharmaceuticals is the largest pharmaceutical company from India and the fifth largest specialty generic company in the world. It has capabilities across dosage forms like injectables, sprays, ointments, creams, liquids, tablets, and capsules.

What is Ranbaxy tablet?

Pregabalin Ranbaxy belongs to a group of medicines used to treat epilepsy, neuropathic pain and Generalised Anxiety Disorder (GAD) in adults. Peripheral and central neuropathic pain: Pregabalin Ranbaxy is used to treat long lasting pain caused by damage to the nerves.

What happened to Ranbaxy?

WHAT HAPPENED TO RANBAXY? They sold it. In 2008, when Ranbaxy was at its peak, Malvinder and Shivinder Singh sold their controlling stake to the Japanese pharma giant Daiichi Sankyo. The Ranbaxy sale earned the brothers a windfall amount of Rs 9,576 crore.

Is Sun Pharma overvalued?

Price to Book Ratio PB vs Industry: SUNPHARMA is overvalued based on its PB Ratio (3.8x) compared to the IN Pharmaceuticals industry average (2.9x).

What does the Sun Pharma-Ranbaxy merger mean for Sun Pharma?

Sun Pharma estimates $250 million of synergies accruing from the merger in three years. Sun Pharma acquired Ranbaxy from Japan’s Daiichi Sankyo for $3.2 billion in stock in addition to assuming $800 million of debt. Sun Pharma has made nearly 20 acquisitions since its inception in 1983.

What happened to Ranbaxy Company Limited?

Ranbaxy B.V., Netherlands, a 100\% subsidiary of Ranbaxy also became a subsidiary of Sun Pharma. Series of deals by Sun pharma is enlisted in Table 3. Shares of Ranbaxy Company Limited stopped trading on 6 th April, 2014. The deal materialized and Sun Pharma have 14\% and 22\% stake respectively after the deal.

What is the difference between Sunsun and Ranbaxy?

Sun’s domestic portfolio has a bias towards specialties including cardiovascular and oral anti-diabetes while Ranbaxy’s domestic portfolio has large primary care and over-the-counter segments as well. Sun will benefit from Ranbaxy’s distribution network as well. Ranbaxy has a strong reach in the rural markets.

Why did Daiichi Sankyo buy Ranbaxy?

Daiichi Sankyo acquired controlling in Ranbaxy in 2008 from its earlier promoters Malvinder Mohan Singh and family. Singh resigned in 2009 after Ranbaxy posted losses and after Daiichi Sankyo decided to get more actively involved in the newly acquired Indian unit.